The effectiveness of vaccines and immunisation in the prevention of major infectious diseases is recognised as one of the greatest successes in medicine. Due to the immunisation programmes of the World Health Organization and partners, the smallpox disease was eradicated and poliomyelitis should be eliminated from the globe in the near future. Special efforts in vaccination with current attenuated vaccines against measles, combined with research on new vaccines based on selected epitopes, and more adequate immunisation strategies for closing the gap of measles susceptibility in young infants, are expected to reduce substantially the measles infection in developing countries, where this disease is a major health problem. In industrialised countries, up to 20% of the population infected with the measles virus are hospitalised and up to 9% surfer from complications, including encephalitis. One in every thousand persons infected with the measles virus will die. The high coverage programmes with measles vaccine had led to a 95% reduction in measles infection in comparison with pre-vaccination era. The elimination of measles and hepatitis B virus infections should be considered a priority for health authorities. Unfortunately, the highly immunogenic and safe vaccine against HBV is not administered worldwide and infection continues to kill. Studies have demonstrated that economic arguments speak for the implementation of universal hepatitis B vaccination. The great majority of countries have introduced the hepatitis B vaccine in their routine infant and adolescent immunisation programmes. It is stressed by experts that hepatitis B vaccine should be given to all children as part of their routine immunisation schedule.

Having modern sophisticated engineering technology, it is possible to accelerate the development of several novel and safe immunogenic vaccines. For example, a new, very effective conjugated meningococcal serogroup C vaccines was produced and introduced into the United Kingdom childhood immunisation programme at the end of 1999. Rapid disappearance of confirmed cases of serogroup C meningococcal disease in vaccinees was noted, suggesting the high efficacy of vaccine. Meningococcal infection is the foremost cause of death by infectious disease. Conjugated vaccines being developed, against meningococcal serogroups A, Y and W, are predicted to be also very effective. With the recent research progress in development of a vaccine against serogroup B meningococcus, the meningococcal diseases will be prevented, in the near future, by effective immunisation. For example, such a safe and highly immunogenic tailor-made vaccine against the New Zealand *Neisseria meningitidis* serogroup B disease epidemic strain was developed.

An interesting progress was made during the recent years to develop vaccines against parasitic infections, such as malaria, schistosomiasis and leishmaniasis. The Walter Reed Army Institute of Research with partners is developing a multi-stage and multi-antigen vaccine to prevent *Plasmodium falciparum* malaria and to limit the severity of the disease in patients that develop malaria. On another hand, promising transmission blocking vaccines against two major species of malaria infecting humans, *P. falciparum* and *Plasmodium vivax*, are presently developed and tested successfully in animals. There is also a new progress in recombinant vaccines for leishmaniasis. Protein antigens common to several Leishmania species were cloned, characterised and first trials demonstrated protective immune responses in humans and in mice.

Several laboratories are currently actively involved in the development of new bacterial vaccines. Peptide and recombinant immunogens for protection against bacterial middle ear infection are reported as strong vaccine candidates against *Moraxella catarrhalis*, the most common causes of bacterial otitis in children. The development and registration of live attenuated vaccines for oral immunisation against bacterial enteric pathogens are underway. A single live oral recombinant vaccine has been licensed for immunisation of humans against cholera. The vaccine strain CVD103-HgR from a wild *Vibrio cholerae* was demonstrated to be very safe and highly immunogenic in humans conferring protection against wild type challenge after administration of a single vaccine dose. As tuberculosis is still causing around 3 million deaths per year, a considerable research effort is underway toward the development of a second generation sub-unit vaccine against *Mycobacterium tuberculosis*. Several immuno-dominant molecules are experimented in sub-unit vaccines. An interesting polyprotein, Mtb72f, was found to be protective in animal models of tuberculosis that resemble human disease. The immunisation trials with candidate Mtb72f vaccine induced protection of cynomolgous monkeys. The DNA vaccination therapy of tuberculosis, experimented in different animal models, is also promising.

Regarding the protection against viral diseases, it should be pointed out that the influenza vaccine is immunogenic, highly cost-effective and cost saving, but under-utilised throughout the world. Influenza infection results in considerable morbidity and mortality, especially in senior population, and in absenteeism at school and at work. The strategies to immunise populations against influenza viral infection, despite of genetic changes in the virus, should be reconsidered with more adequate advertising on benefits to vaccinees and on fast return of investment into vaccination campaigns. Recent data with intranasally administered trivalent, live, attenuated influenza vaccine, proved its effectiveness, efficacy and safety. The vaccine efficacy was 95% against lower respiratory infection and 96% against febrile illness. The new adjuvanted influenza vaccine with novel adjuvants demonstrated that the addition of MF59 adjuvant emulsion to sub-unit influenza vaccines enhances a high immune response in the elderly. The vaccine is well tolerated and safe. Also the DNA vaccination and RNA immunoprophylaxis eliciting protective immunity against influenza infection are investigated with genetic vaccine candidates. Mice vaccinated with liposome-encapsulated plasmid DNA intranasally or intramuscularly were fully protected, while naked DNA provided only partial protection. Immunoprophylaxis with polyriboinosinic--polyribocytidylic dsRNA encapsulated in liposomes also induced protection against virus challenge in mice. These approaches merit full attention for the eventual prevention of respiratory influenza illness as alternatives to current vaccines and immunisation measures. In Canada and Japan, interesting data was obtained in developing vaccines against the coronavirus, agent of severe acute respiratory syndrome (SARS), using nucleic acid-based immunomodulators and cDNA constructs encoding the structural antigens. The SARS DNA vaccines inducing human neutralising antibodies are under investigation. The development of a synthetic peptide vaccine to treat chronic hepatitis C is of great interest as worldwide only half of 170 million patients do respond to interferon/ribavarin treatment. As the Japanese encephalitis is still endemic in Japan and other regions of Asia, the next generation of vaccine against JEV, safe and immunogenic, is promising to reduce the major cause of paediatric encephalitis in South and South-East Asia.

Genetic vaccination is predicted to have a promising future. Post-exposure DNA vaccination protects mice against rabies virus and investigations of the efficacy of HIV-1 DNA vaccines in humans support this approach. Despite unlimited efforts and important financial resources given to multiple projects to develop a vaccine against the human immunodeficiency virus disease AIDS, the results obtained are not conclusive. Pre-clinical and clinical studies demonstrated that neutralising antibodies are protective and that ADCC could play a role in controlling acute viral infection. Some immunisation protocols have revealed the inducing of HIV specific humoral and cellular responses in human vaccinees. A lot of interesting data is accumulated by several groups, but in the presence of a virus, which is genetically extremely variable, in the absence of biological correlates of protection and of a reliable animal model, the development of a vaccine against the human immunodeficiency viruses remains a formidable challenge.

Interesting research trends in paediatric vaccination are the development of combination vaccines with aim to immunise against several diseases and to reduce the number of shots required. Currently, various childhood combination vaccines are under investigation or already licensed. For example, to diphtheria--tetanus--accellular pertussis antigens were added *Haemophilus influenzae* type b glycoconjugate vaccine, hepatitis B and inactivated polio vaccines. It was reported that such combination vaccines elicit very high immune responses for all components, with the exception of Hib for which a decrease of antibodies is noted, probably due to interference between vaccine components and glycoconjugates. The combination of components having similar characteristics is more compatible to avoid eventual interference problems. However, it was reported that the new liquid hexavalent vaccine containing diphtheria, tetanus, two-component acellular pertussis, inactivated polio virus, *Haemophilus influenzae* type b and hepatitis B virus antigens resulted in protective immune responses to all antigens. The immune response elicited by the novel formulation of combined hepatitis A and B vaccine, compares well with sero-responses obtained after administration of monovalent vaccines. The new seven valent pneumococcal conjugate vaccine (7VPnC) have proven efficacy and safety against pneumococcal diseases and otitis in infants, and elicit a significant antibody responses to each pneumococcal vaccine serotypes. It is predicted that this multivalent vaccine will play an important role in paediatric prevention of invasive and non-invasive pneumococcal diseases. *Streptococcus pneumoniae* is a leading cause of pneumococcal infections and accounts, respectively, for up to 40 and 50% of all cases of bacterial meningitis and bacterial otitis. The task for the future paediatric immunisation is to develop multivalent combination vaccines.

In search of vaccine efficiency, significant attention is given to the concept of mucosal immunisation. With the progressing knowledge of mucosal immunoregulation, on new technologies for vaccine delivery, immunomodulation and immunopotentiators, the immunisation of mucosal surfaces has become very attractive. To induce immune responses, most vaccines, when administered mucosally, need the use of strong, non-toxic adjuvants. The new generation of cholera toxin and *Escherichia coli* enterotoxin are non-toxic and powerful mucosal adjuvants, able to elicit high immune responses. Also, the recent research on oral plant-based vaccines is of great interest. Plants are being used for production of bio-medical components, including prophylactic vaccines and therapeutic antibodies. The first clinical trials in human volunteers with potatoes expressing the hepatitis B surface antigen and with other plant candidate vaccines are currently investigated. There are hopes, that in the future, the use of plant-based technologies and cost-effective production of vaccines will circumvent the limitations on production and accessibility to vaccines, especially in developing regions of the world.

Many research investigators reported a substantial progress in anti-cancer and disease therapeutic vaccines with the discovery and development of antigens for tumour immunotherapy. Studies in patients with therapeutic candidate vaccines against melanoma and colorectal cancer and on human papilloma virus in pre-invasive and invasive cervical cancer provides incentives for clinical applications of potential immunotherapy. Clinical trials of vaccines against breast cancer, for leukaemia and lung cancer are progressing satisfactorily. Site-specific peptide vaccines for immunotherapy and immunisation against cancer, infectious diseases, chronic diseases and for veterinary applications using the core technologies carry great expectations.

The WCVI 2004 in Japan confirmed that we are in a new era of vaccinology with sophisticated technologies to produce immunogenic safe vaccines and modern immunisation strategies in preventing and controlling diseases. The novel approaches promoting the accessibility of all to vaccines and immunisation at affordable price, and the creation of new, less bureaucratic partnership groups, will help to achieve these humanitarian goals.
